This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
Only randomised controlled trials (RCTs) evaluating PPI therapy in NUD were included. The inclusion criteria included: adult patients; patients with dyspepsia who fulfilled Rome or Working Party definitions; negative findings at endoscopy; the study evaluated intervention with a PPI, using a comparison group that was either placebo, H2-receptor antagonists, prokinetic therapy, antiacids or mucosal protecting agents; and the outcome assessed was symptoms of dyspepsia.
The exclusion criteria were: trials that evaluated only patients with symptoms of gastroesophageal reflux disease; trials that evaluated only patients who were predominantly (>20%) taking non-steroidal anti-inflammatory drugs; and trials assessing outcomes at less than 1 week.
Sources searched to identify primary studies
The systematic review used was conducted using Cochrane Collaboration methodology. The Cochrane Controlled Trials Register, MEDLINE, EMBASE and CINAHL were searched. Grey literature was searched using the SIGLE database. All these databases were searched until September 2002. Experts in the field of dyspepsia and pharmaceutical companies were contacted for unpublished materials. Recent relevant gastroenterology journals were handsearched.
Criteria used to ensure the validity of primary studies
The quality of the trials was evaluated according to the BMJ criteria.
Methods used to judge relevance and validity, and for extracting data
A single reviewer extracted the data from eligible trials on a standardised form. A second investigator conducted an unblinded check on the accuracy of the information.
Number of primary studies included
Six papers, reporting eight international trials, were identified.
Methods of combining primary studies
The efficacy data were combined using a random-effects meta-analysis.
Investigation of differences between primary studies
There was statistically significant heterogeneity between the trials (heterogeneity chi-squared 30.05, d.f.=7, p<0.001). The variation in results between studies was not associated with the prevalence of Helicobacter pylori, gastroesophageal reflux symptoms, or duration of treatment. No statistically significant heterogeneity was associated with different doses of PPI.
In terms of comparisons with other studies, the authors stated that this was the first systematic review evaluating the efficacy of PPI therapy in NUD. Although the trials selected were international, the issue of the generalisability of the findings to other settings was not addressed. The authors discussed appropriately the limitations of the meta-analysis and the economic analysis.
